BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Magee N, Zou A, Zhang Y. Pathogenesis of Nonalcoholic Steatohepatitis: Interactions between Liver Parenchymal and Nonparenchymal Cells. Biomed Res Int. 2016;2016:5170402. [PMID: 27822476 DOI: 10.1155/2016/5170402] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Magee N, Zou A, Ghosh P, Ahamed F, Delker D, Zhang Y. Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis. Journal of Biological Chemistry 2020;295:994-1008. [DOI: 10.1016/s0021-9258(17)49910-8] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Khomich O, Ivanov AV, Bartosch B. Metabolic Hallmarks of Hepatic Stellate Cells in Liver Fibrosis. Cells 2019;9:E24. [PMID: 31861818 DOI: 10.3390/cells9010024] [Cited by in Crossref: 28] [Cited by in F6Publishing: 35] [Article Influence: 9.3] [Reference Citation Analysis]
3 Matboli M, Gadallah SH, Rashed WM, Hasanin AH, Essawy N, Ghanem HM, Eissa S. mRNA-miRNA-lncRNA Regulatory Network in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:6770. [PMID: 34202571 DOI: 10.3390/ijms22136770] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Millings EJ, De Rosa MC, Fleet S, Watanabe K, Rausch R, Egli D, Li G, Leduc CA, Zhang Y, Fischer SG, Leibel RL. ILDR2 has a negligible role in hepatic steatosis. PLoS One 2018;13:e0197548. [PMID: 29847571 DOI: 10.1371/journal.pone.0197548] [Reference Citation Analysis]
5 Ilan Y, Shailubhai K, Sanyal A. Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASH. Clin Exp Immunol 2018;193:275-83. [PMID: 29920654 DOI: 10.1111/cei.13159] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
6 Shimizu Y, Tamura T, Kemmochi A, Owada Y, Ozawa Y, Hisakura K, Matsuzaka T, Shimano H, Nakano N, Sakashita S, Oda T, Ohkohchi N. Oxidative stress and Liver X Receptor agonist induce hepatocellular carcinoma in Non-alcoholic steatohepatitis model. J Gastroenterol Hepatol 2021;36:800-10. [PMID: 32870526 DOI: 10.1111/jgh.15239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Atif M, Warner S, Oo YH. Linking the gut and liver: crosstalk between regulatory T cells and mucosa-associated invariant T cells. Hepatol Int 2018;12:305-14. [PMID: 30027532 DOI: 10.1007/s12072-018-9882-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
8 Imran M, Sergent O, Tête A, Gallais I, Chevanne M, Lagadic-Gossmann D, Podechard N. Membrane Remodeling as a Key Player of the Hepatotoxicity Induced by Co-Exposure to Benzo[a]pyrene and Ethanol of Obese Zebrafish Larvae. Biomolecules 2018;8:E26. [PMID: 29757947 DOI: 10.3390/biom8020026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Su Q, Kumar V, Sud N, Mahato RI. MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis. Adv Drug Deliv Rev. 2018;129:54-63. [PMID: 29391222 DOI: 10.1016/j.addr.2018.01.009] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 12.8] [Reference Citation Analysis]
10 Antonucci L, Porcu C, Timperi E, Santini SJ, Iannucci G, Balsano C. Circulating Neutrophils of Nonalcoholic Steatohepatitis Patients Show an Activated Phenotype and Suppress T Lymphocytes Activity. J Immunol Res 2020;2020:4570219. [PMID: 32671116 DOI: 10.1155/2020/4570219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Modares Mousavi SR, Geramizadeh B, Anushiravani A, Ejtehadi F, Anbardar MH, Moini M. Correlation between Serum Ferritin Level and Histopathological Disease Severity in Non-alcoholic Fatty Liver Disease. Middle East J Dig Dis 2018;10:90-5. [PMID: 30013757 DOI: 10.15171/mejdd.2018.96] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
12 Kostrzewski T, Snow S, Battle AL, Peel S, Ahmad Z, Basak J, Surakala M, Bornot A, Lindgren J, Ryaboshapkina M, Clausen M, Lindén D, Maass C, Young LM, Corrigan A, Ewart L, Hughes D. Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system. Commun Biol 2021;4:1080. [PMID: 34526653 DOI: 10.1038/s42003-021-02616-x] [Reference Citation Analysis]
13 Magee N, Zou A, Ghosh P, Ahamed F, Delker D, Zhang Y. Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis. J Biol Chem 2020;295:994-1008. [PMID: 31831621 DOI: 10.1074/jbc.RA119.010233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
14 Beheshti A, Chakravarty K, Fogle H, Fazelinia H, Silveira WAD, Boyko V, Polo SL, Saravia-Butler AM, Hardiman G, Taylor D, Galazka JM, Costes SV. Multi-omics analysis of multiple missions to space reveal a theme of lipid dysregulation in mouse liver. Sci Rep 2019;9:19195. [PMID: 31844325 DOI: 10.1038/s41598-019-55869-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
15 Chow MD, Lee YH, Guo GL. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mol Aspects Med. 2017;56:34-44. [PMID: 28442273 DOI: 10.1016/j.mam.2017.04.004] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 10.6] [Reference Citation Analysis]
16 Ale-Ebrahim M, Rahmani R, Faryabi K, Mohammadifar N, Mortazavi P, Karkhaneh L. Atheroprotective and hepatoprotective effects of trans-chalcone through modification of eNOS/AMPK/KLF-2 pathway and regulation of COX-2, Ang-II, and PDGF mRNA expression in NMRI mice fed HCD. Mol Biol Rep 2022. [PMID: 35190927 DOI: 10.1007/s11033-022-07174-x] [Reference Citation Analysis]
17 Kim KH, Lee MS. GDF15 as a central mediator for integrated stress response and a promising therapeutic molecule for metabolic disorders and NASH. Biochim Biophys Acta Gen Subj 2021;1865:129834. [PMID: 33358864 DOI: 10.1016/j.bbagen.2020.129834] [Reference Citation Analysis]
18 Zou A, Magee N, Deng F, Lehn S, Zhong C, Zhang Y. Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis. J Biol Chem 2018;293:8656-71. [PMID: 29666185 DOI: 10.1074/jbc.RA117.001653] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
19 Li Y, Lu Z, Ru JH, Lopes-Virella MF, Lyons TJ, Huang Y. Saturated fatty acid combined with lipopolysaccharide stimulates a strong inflammatory response in hepatocytes in vivo and in vitro. Am J Physiol Endocrinol Metab 2018;315:E745-57. [PMID: 29989851 DOI: 10.1152/ajpendo.00015.2018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
20 Montandon SA, Somm E, Loizides-Mangold U, de Vito C, Dibner C, Jornayvaz FR. Multi-technique comparison of atherogenic and MCD NASH models highlights changes in sphingolipid metabolism. Sci Rep. 2019;9:16810. [PMID: 31728041 DOI: 10.1038/s41598-019-53346-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
21 Arroyave-Ospina JC, Wu Z, Geng Y, Moshage H. Role of Oxidative Stress in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Implications for Prevention and Therapy. Antioxidants (Basel) 2021;10:174. [PMID: 33530432 DOI: 10.3390/antiox10020174] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 15.0] [Reference Citation Analysis]
22 Delaune V, Orci LA, Lacotte S, Peloso A, Schrenzel J, Lazarevic V, Toso C. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response. Expert Opin Biol Ther 2018;18:1061-71. [PMID: 30173562 DOI: 10.1080/14712598.2018.1518424] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
23 von Loeffelholz C, Coldewey SM, Birkenfeld AL. A Narrative Review on the Role of AMPK on De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease: Evidence from Human Studies. Cells 2021;10:1822. [PMID: 34359991 DOI: 10.3390/cells10071822] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Kim H, Im I, Jeon JS, Kang E, Lee H, Jo S, Kim J, Woo D, Choi YJ, Kim HJ, Han J, Lee B, Kim J, Kim SK, Park H. Development of human pluripotent stem cell-derived hepatic organoids as an alternative model for drug safety assessment. Biomaterials 2022;286:121575. [DOI: 10.1016/j.biomaterials.2022.121575] [Reference Citation Analysis]
25 Armstrong LE, Guo GL. Role of FXR in Liver Inflammation during Nonalcoholic Steatohepatitis. Curr Pharmacol Rep 2017;3:92-100. [PMID: 28983452 DOI: 10.1007/s40495-017-0085-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
26 Kurniawan DW, Storm G, Prakash J, Bansal R. Role of spleen tyrosine kinase in liver diseases. World J Gastroenterol 2020; 26(10): 1005-1019 [PMID: 32205992 DOI: 10.3748/wjg.v26.i10.1005] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
27 Kim JW, Zhou Z, Yun H, Park S, Choi SJ, Lee SH, Lim CW, Lee K, Kim B. Cigarette smoking differentially regulates inflammatory responses in a mouse model of nonalcoholic steatohepatitis depending on exposure time point. Food Chem Toxicol 2020;135:110930. [PMID: 31678261 DOI: 10.1016/j.fct.2019.110930] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
28 Cole BK, Feaver RE, Wamhoff BR, Dash A. Non-alcoholic fatty liver disease (NAFLD) models in drug discovery. Expert Opin Drug Discov 2018;13:193-205. [PMID: 29190166 DOI: 10.1080/17460441.2018.1410135] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 8.2] [Reference Citation Analysis]
29 Kruger AJ, Fuchs BC, Masia R, Holmes JA, Salloum S, Sojoodi M, Ferreira DS, Rutledge SM, Caravan P, Alatrakchi N. Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis. Hepatol Commun. 2018;2:529-545. [PMID: 29761169 DOI: 10.1002/hep4.1160] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
30 Piras IS, Gerhard GS, DiStefano JK. Palmitate and Fructose Interact to Induce Human Hepatocytes to Produce Pro-Fibrotic Transcriptional Responses in Hepatic Stellate Cells Exposed to Conditioned Media. Cell Physiol Biochem 2020;54:1068-82. [PMID: 33095528 DOI: 10.33594/000000288] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Atanasovska B, Rensen SS, Marsman G, Shiri-Sverdlov R, Withoff S, Kuipers F, Wijmenga C, van de Sluis B, Fu J. Long Non-Coding RNAs Involved in Progression of Non-Alcoholic Fatty Liver Disease to Steatohepatitis. Cells 2021;10:1883. [PMID: 34440652 DOI: 10.3390/cells10081883] [Reference Citation Analysis]
32 Ramos-Tovar E, Muriel P. Free radicals, antioxidants, nuclear factor-E2-related factor-2 and liver damage. J Appl Toxicol 2020;40:151-68. [PMID: 31389060 DOI: 10.1002/jat.3880] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
33 Klieser E, Mayr C, Kiesslich T, Wissniowski T, Fazio PD, Neureiter D, Ocker M. The Crosstalk of miRNA and Oxidative Stress in the Liver: From Physiology to Pathology and Clinical Implications. Int J Mol Sci 2019;20:E5266. [PMID: 31652839 DOI: 10.3390/ijms20215266] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
34 Wu PJ, Chen JB, Lee WC, Ng HY, Lien SC, Tsai PY, Wu CH, Lee CT, Chiou TT. Oxidative Stress and Nonalcoholic Fatty Liver Disease in Hemodialysis Patients. Biomed Res Int 2018;2018:3961748. [PMID: 30515395 DOI: 10.1155/2018/3961748] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
35 Wan Y, Bao X, Huang J, Zhang X, Liu W, Cui Q, Jiang D, Wang Z, Liu R, Wang Q. Novel GLP-1 Analog Supaglutide Reduces HFD-Induced Obesity Associated with Increased Ucp-1 in White Adipose Tissue in Mice. Front Physiol 2017;8:294. [PMID: 28555111 DOI: 10.3389/fphys.2017.00294] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
36 Chen J, Deng X, Liu Y, Tan Q, Huang G, Che Q, Guo J, Su Z. Kupffer Cells in Non-alcoholic Fatty Liver Disease: Friend or Foe? Int J Biol Sci 2020;16:2367-78. [PMID: 32760204 DOI: 10.7150/ijbs.47143] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
37 Nageeb MM, Khatab MI, Abdel-Sameea AA, Teleb NA. Adelmidrol protects against non-alcoholic steatohepatitis in mice. Naunyn Schmiedebergs Arch Pharmacol 2020;393:777-84. [PMID: 31853615 DOI: 10.1007/s00210-019-01785-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
38 Lee Y, Hu S, Park YK, Lee JY. Health Benefits of Carotenoids: A Role of Carotenoids in the Prevention of Non-Alcoholic Fatty Liver Disease. Prev Nutr Food Sci 2019;24:103-13. [PMID: 31328113 DOI: 10.3746/pnf.2019.24.2.103] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
39 Nair B, Nath LR. Inevitable role of TGF-β1 in progression of nonalcoholic fatty liver disease. Journal of Receptors and Signal Transduction 2020;40:195-200. [DOI: 10.1080/10799893.2020.1726952] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
40 Tahmasebi S, Neishaboori H, Jafari D, Faghihzadeh E, Esmaeilzadeh A, Mirshafiey A. The effects of guluronic acid (G2013), a new emerging treatment, on inflammatory factors in nonalcoholic steatohepatitis patients under in vitro conditions. Immunopharmacol Immunotoxicol 2021;:1-9. [PMID: 34314306 DOI: 10.1080/08923973.2021.1954946] [Reference Citation Analysis]
41 Brigstock DR. Extracellular Vesicles in Organ Fibrosis: Mechanisms, Therapies, and Diagnostics. Cells 2021;10:1596. [PMID: 34202136 DOI: 10.3390/cells10071596] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
42 Yan FJ, Wang X, Wang SE, Hong HT, Lu J, Ye Q, Zheng YL, Wang YJ. C-Jun/C7ORF41/NF-κB axis mediates hepatic inflammation and lipid accumulation in NAFLD. Biochem J 2020;477:691-708. [PMID: 31957809 DOI: 10.1042/BCJ20190799] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
43 Daou N, Viader A, Cokol M, Nitzel A, Chakravarthy MV, Afeyan R, Tramontin T, Marukian S, Hamill MJ. A novel, multitargeted endogenous metabolic modulator composition impacts metabolism, inflammation, and fibrosis in nonalcoholic steatohepatitis-relevant primary human cell models. Sci Rep 2021;11:11861. [PMID: 34088912 DOI: 10.1038/s41598-021-88913-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Kupčová V, Fedelešová M, Bulas J, Kozmonová P, Turecký L. Overview of the Pathogenesis, Genetic, and Non-Invasive Clinical, Biochemical, and Scoring Methods in the Assessment of NAFLD. Int J Environ Res Public Health 2019;16:E3570. [PMID: 31554274 DOI: 10.3390/ijerph16193570] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
45 Ge XJ, Du YX, Zheng LM, Wang M, Jiang JY. Mortality trends of liver cancer among patients with type 2 diabetes at the global and national level. J Diabetes Complications 2020;34:107612. [PMID: 32402842 DOI: 10.1016/j.jdiacomp.2020.107612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Sulaiman SA, Muhsin NIA, Jamal R. Regulatory Non-coding RNAs Network in Non-alcoholic Fatty Liver Disease. Front Physiol 2019;10:279. [PMID: 30941061 DOI: 10.3389/fphys.2019.00279] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
47 Wu H, Ni X, Xu Q, Wang Q, Li X, Hua J. Regulation of lipid‐induced macrophage polarization through modulating peroxisome proliferator‐activated receptor‐gamma activity affects hepatic lipid metabolism via a Toll‐like receptor 4/NF‐κB signaling pathway. Journal of Gastroenterology and Hepatology 2020;35:1998-2008. [DOI: 10.1111/jgh.15025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
48 Wisniewski PJ, Dowden RA, Campbell SC. Role of Dietary Lipids in Modulating Inflammation through the Gut Microbiota. Nutrients 2019;11:E117. [PMID: 30626117 DOI: 10.3390/nu11010117] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
49 Choi HSJ, Brouwer WP, Zanjir WMR, de Man RA, Feld JJ, Hansen BE, Janssen HLA, Patel K. Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B. Hepatology. 2020;71:539-548. [PMID: 31309589 DOI: 10.1002/hep.30857] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 11.3] [Reference Citation Analysis]
50 Kim KH, Lee MS. Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches. Front Endocrinol (Lausanne). 2018;9:485. [PMID: 30197624 DOI: 10.3389/fendo.2018.00485] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
51 Prins GH, Luangmonkong T, Oosterhuis D, Mutsaers HAM, Dekker FJ, Olinga P. A Pathophysiological Model of Non-Alcoholic Fatty Liver Disease Using Precision-Cut Liver Slices. Nutrients 2019;11:E507. [PMID: 30818824 DOI: 10.3390/nu11030507] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
52 Pei K, Gui T, Kan D, Feng H, Jin Y, Yang Y, Zhang Q, Du Z, Gai Z, Wu J, Li Y. An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease. Biomed Res Int. 2020;2020:4020249. [PMID: 32733940 DOI: 10.1155/2020/4020249] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
53 Hanson A, Wilhelmsen D, DiStefano JK. The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD). Noncoding RNA 2018;4:E18. [PMID: 30134610 DOI: 10.3390/ncrna4030018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
54 Singh MK, Das BK, Choudhary S, Gupta D, Patil UK. Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management. Biomed Pharmacother 2018;106:991-1002. [PMID: 30119271 DOI: 10.1016/j.biopha.2018.06.095] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
55 Lake AD, Hardwick RN, Leamon CP, Low PS, Cherrington NJ. Folate receptor-beta expression as a diagnostic target in human & rodent nonalcoholic steatohepatitis. Toxicol Appl Pharmacol 2019;368:49-54. [PMID: 30794826 DOI: 10.1016/j.taap.2019.02.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
56 Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018;15:349-364. [PMID: 29740166 DOI: 10.1038/s41575-018-0009-6] [Cited by in Crossref: 197] [Cited by in F6Publishing: 196] [Article Influence: 65.7] [Reference Citation Analysis]
57 de Oliveira DG, de Faria Ghetti F, Moreira APB, Hermsdorff HHM, de Oliveira JM, de Castro Ferreira LEVV. Association between dietary total antioxidant capacity and hepatocellular ballooning in nonalcoholic steatohepatitis: a cross-sectional study.Eur J Nutr. 2019;58:2263-2270. [PMID: 30019089 DOI: 10.1007/s00394-018-1776-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
58 Sweet PH, Khoo T, Nguyen S. Nonalcoholic Fatty Liver Disease. Primary Care: Clinics in Office Practice 2017;44:599-607. [DOI: 10.1016/j.pop.2017.07.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
59 Molenaar MR, Penning LC, Helms JB. Playing Jekyll and Hyde-The Dual Role of Lipids in Fatty Liver Disease. Cells 2020;9:E2244. [PMID: 33036257 DOI: 10.3390/cells9102244] [Reference Citation Analysis]
60 Prins GH, Rios-Morales M, Gerding A, Reijngoud DJ, Olinga P, Bakker BM. The Effects of Butyrate on Induced Metabolic-Associated Fatty Liver Disease in Precision-Cut Liver Slices. Nutrients 2021;13:4203. [PMID: 34959755 DOI: 10.3390/nu13124203] [Reference Citation Analysis]